Divide & Conquer, Developing New Class of Cancer Therapeutics to Disrupt Cell-to-Cell Communication, Emerges from Stealth as New Paper by Co-Founder is Published in Nature
https://www.businesswire.com/news/home/20190918005802/en/
CAMBRIDGE, England--(BUSINESS WIRE)--Sep 18, 2019--
Divide & Conquer (“ D&C ”), a biotechnology company formed in 2018 with a £10 million (approximately $13.1 million) Series A financing from Medicxi. has left stealth mode to mark the publication of another paper in Nature co-authored by one of its founders, Prof. Frank Winkler of Heidelberg University.
